Loading viewer...
investor_presentation
Format: PDF investor_presentation
Tonix Pharmaceuticals presents Tonmya (TNX-102 SL), an FDA-conditionally accepted drug candidate for fibromyalgia management. The presentation details fibromyalgia as a chronic overlapping pain condition and nociplastic syndrome, positioning Tonmya within the CNS portfolio alongside existing FDA-approved fibromyalgia treatments.
investor_presentation
48 Pages
investor_presentation
45 Pages
JSW Steel
Zentalis Pharmaceuticals 2023 Corporate Presentation
investor_presentationinvestor_presentation
47 Pages
Zentalis Pharmaceuticals, Inc.